California’s Assembly has overwhelmingly approved proposed legislation (S.B. 598) that would require pharmacists to inform physicians if they dispense biosimilar drugs as a substitute for biologic medication. Organizations representing pharmacist interests have challenged the measure, calling the work required unnecessary and the bill premature because the federal government has yet to approve a biosimilar or finalize biosimilar approval regulations. They also suggest that a physician notification provision will create a psychological barrier to prescribing biosimilars. The legislation has also passed the full state Senate. See California Healthline, August 22, 2013; Business Week, August 27, 2013.